Zenas BioPharma (NASDAQ:ZBIO) saw its stock price rise by 13.8% during trading, closing at $26.48 with reduced trading volume. Analysts have issued new price targets for ZBIO, with a consensus “Moderate Buy” rating and an average price target of $43.14. Insider transactions show CEO Leon O. Moulder, Jr. recently increased his stake in the company.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% Higher - What's Next?
Zenas BioPharma (NASDAQ:ZBIO) saw its stock price rise by 13.8% during trading, closing at $26.48 with reduced trading volume. Analysts have issued new price targets for ZBIO, with a consensus “Moderate Buy” rating and an average price target of $43.14. Insider transactions show CEO Leon O. Moulder, Jr. recently increased his stake in the company.